Search

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.

Therapeutic area :

Berg van der P., Ruppert M., Mesic E., Snelder N., Seelmann A., Heinig R., Joseph A., Garmann D., Lippert J., Eissing T. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis. PAGE 2022. [Link to publication]

Our expertise

Lung Diseases Diabetes Anesthesiology Cardiovascular Anti-infectives and immunology CNS Oncology Biologicals Blood disorders Peripheral Nervous System Endocrinology/Sexual health General modelling Methods Safety pharmacology Pain Gastrointestinal Diseases Paediatrics